eligibility_summary
Eligibility: Adults (≥18) with unresectable locally advanced or metastatic urothelial carcinoma (any histology), stage IV at start of first-line chemo, completed first-line platinum chemo without progression (SD/PR/CR), receiving/received ≥1 dose of avelumab as first-line maintenance per label, consent provided (waiver allowed for deceased/lost). Exclusion: participation in any interventional drug/device trial within 28 days before avelumab maintenance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT05568407 evaluated avelumab as real‑world maintenance therapy after first‑line platinum chemo in advanced/metastatic urothelial cancer. Intervention: Avelumab, a human IgG1 monoclonal antibody immune checkpoint inhibitor targeting PD‑L1. Mechanism: Blocks PD‑L1 on tumor and immune cells from binding PD‑1 and B7.1 (CD80), restoring antitumor T‑cell activity, its IgG1 Fc can trigger ADCC via Fcγ receptors on NK cells/macrophages. Targets/pathways: PD‑1/PD‑L1 axis, B7.1 interactions, PD‑L1–expressing tumor/APCs, effector T cells, NK cells. Study was observational and terminated for poor accrual.